Detalhe da pesquisa
1.
A benchmark for dose-finding studies with unknown ordering.
Biostatistics
; 23(3): 721-737, 2022 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33409536
2.
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.
World J Urol
; 41(9): 2381-2388, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37480491
3.
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
J Pathol
; 256(1): 108-118, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611919
4.
Survival after sentinel lymph node biopsy for early cervical cancers: a systematic review and meta-analysis.
Int J Gynecol Cancer
; 33(12): 1853-1860, 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696646
5.
Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis.
Gynecol Oncol
; 164(2): 446-454, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34949436
6.
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research.
Lancet Oncol
; 22(8): e369-e376, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216541
7.
A benchmark for dose finding studies with continuous outcomes.
Biostatistics
; 21(2): 189-201, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30165594
8.
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecol Oncol
; 161(2): 502-507, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33612336
9.
Change-point joint model for identification of plateau of activity in early phase trials.
Stat Med
; 40(9): 2113-2138, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33561898
10.
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Future Oncol
; 17(14): 1811-1823, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33543650
11.
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.
Breast Cancer Res
; 22(1): 55, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32460829
12.
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Int J Gynecol Cancer
; 30(12): 1997-2001, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32606097
13.
A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Clin Trials
; 17(5): 522-534, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32631095
14.
Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies.
Biom J
; 62(7): 1717-1729, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32529689
15.
Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Clin Trials
; 16(6): 635-644, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31538815
16.
Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
J Biopharm Stat
; 29(2): 359-377, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30352007
17.
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
Br J Cancer
; 119(8): 937-939, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30327567
18.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Invest New Drugs
; 36(1): 62-74, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597151
19.
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Pediatr Blood Cancer
; 64(1): 25-31, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27555472
20.
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Clin Trials
; 14(6): 611-620, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28764555